Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
PRPH 
ProPhase Labs Inc (PRPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: PRPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.8
1 Year Target Price $13.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.12% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.30M USD | Price to earnings Ratio - | 1Y Target Price 13.8 |
Price to earnings Ratio - | 1Y Target Price 13.8 | ||
Volume (30-day avg) 1 | Beta -0.64 | 52 Weeks Range 0.11 - 0.93 | Updated Date 12/13/2025 |
52 Weeks Range 0.11 - 0.93 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -539.52% |
Management Effectiveness
Return on Assets (TTM) -23.5% | Return on Equity (TTM) -220.34% |
Valuation
Trailing PE - | Forward PE 10.09 | Enterprise Value 12580351 | Price to Sales(TTM) 1.05 |
Enterprise Value 12580351 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 2.49 | Enterprise Value to EBITDA 2.45 | Shares Outstanding 46179017 | Shares Floating 42845816 |
Shares Outstanding 46179017 | Shares Floating 42845816 | ||
Percent Insiders 7.55 | Percent Institutions 6.89 |
About ProPhase Labs Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 1997-01-16 | Chairman & CEO Mr. Ted William Karkus | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 96 | Website https://www.prophaselabs.com |
Full time employees 96 | Website https://www.prophaselabs.com | ||
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.